Home » News » 01/06 » GlaxoSmithKline pays $5m milestone to Human Genome Sciences

GlaxoSmithKline pays $5m milestone to Human Genome Sciences

Date published: 17/01/2006

GlaxoSmithKline (GSK) has made a $5 million milestone payment to its collaborator Human Genome Sciences. The payment comes as GSK is to file an Investigational New Drug (IND) application to begin Phase I clinical trials of diabetes treatment GSK716155 (formerly known as Albugon).

Under the agreement, which has already seen GSK pay $12 million, total payments have the potential to reach $183 million, as well as any royalties on products developed and marketed. H Thomas Watkins, president and chief executive of Human Genome Sciences, said: "We are pleased that GSK has chosen to advance GSK716155 to clinical development.

"It is our hope that this drug may ultimately offer a new option in the treatment of diabetes. We view the agreement as a strong indication of the potential of our albumin-fusion technology, and we look forward to continuing our support of GSK on this important program."

© Adfero Ltd

Disclaimer

AllAboutMedicalSales excludes any warranty, express or implied, as to the quality, accuracy, timeliness, completeness or fitness for a particular purpose of this briefing. AllAboutMedicalSales will not be liable for any claims, penalties, losses, damages, costs, or expenses arising from the use of or inability to use this briefing or from any unauthorised access to or alteration of the Briefing. AllAboutMedicalSales makes no warranty that the contents of this briefing are compatible with all computer systems and browsers.